Abstract

Single antimicrobial therapy has been unable to resist the global spread of bacterial resistance. Literatures of available in vitro and in vivo studies were reviewed and the results showed that low frequency ultrasound (LFU) has a promising synergistic bactericidal effect with antibiotics against both planktonic and biofilm bacteria. It also can facilitate the release of antibiotics from medical implants. As a noninvasive and targeted therapy, LFU has great potential in treating bacterial infections. However, more in-depth and detailed studies are still needed before LFU is officially applied as a combination therapy in the field of anti-infective treatment.

1. Introduction

After the application of the first antibiotic penicillin, a series of natural, semisynthetic, and synthetic antimicrobials were discovered and applied in clinics, achieving great progress in bacterial infection therapy and saving millions of lives at the golden age of antibiotics [1]. However, many decades later, bacterial infections have again become a serious threat due to lack of new drug development and rapid emergence of resistant bacteria. Facing the global “antibiotic resistance crisis,” we are now in the “postantibiotic era” [2]. For example, tigecycline and colistin are the last-resort antibiotics for multidrug resistant (MDR) Acinetobacter, which is defined as a serious threat to human health [3]. Unfortunately, tigecycline-resistant Acinetobacter baumannii was reported only 2 years after tigecycline was approved by FDA in 2005 [4]. Colistin heteroresistant and resistant A. baumannii have also been described worldwide [5]. In this context, antimicrobial combination therapy has become an option to treat infection with MDR bacteria because of broad coverage and synergistic effect. However, it also brings higher risk of adverse events, leading to treatment failure, increased antibiotic use, and possible accelerated emergence of drug resistance [6].

Overall, we need other methods to confront the growing problem of bacterial resistance. Low frequency ultrasound (LFU) is one of the safe and promising physical methods [7]. Ultrasound, a pressure sound wave with frequency of 20 kHz or more, has been used for decades in research and diagnostics. LFU generally has a frequency ranging from 20 to 100 kHz and is also termed as high-power ultrasound [8]. It is believed that the acoustic cavitation, or the growth and collapse of microbubbles in liquid media, is the underlying mechanism for the bactericidal effects of ultrasound because it could generate mechanical forces such as shock waves, shear forces, and microjets to damage microorganisms [9]. The stable cavitation and radiation pressure will generate multidirectional acoustic microstreams, which will produce a high shear stress to enhance the release and delivery of antibiotic from imbedded implants [10]. With other advantages such as beam directivity and capability of treating deep tissue targets without tissue damage, LFU has been reported in series of studies to be a promising method to enhance the antibiotic action on bacteria. Based on available in vitro and in vivo data, we aimed to evaluate the synergistic effects of LFU and antibiotics combination therapy in future clinical practice in this review.

2. Synergistic Effects of LFU and Antibiotics against Planktonic Bacteria

Although many studies showed that LFU alone can significantly reduce bacterial counts [8, 1113], Pitt et al. [14] first confirmed the synergistic effects of LFU and antibiotics in 1994 (Table 1). They evaluated the combination of LFU and gentamicin against planktonic cultures of Pseudomonas aeruginosa (P. aeruginosa), Escherichia coli (E. coli), Staphylococcus epidermidis (S. epidermidis), and Staphylococcus aureus (S. aureus) and found that, at the level of 67 kHz and 0.3 W/cm2 intensity, continuous ultrasound alone had no bacteria inhibitory or bactericidal activity, but, in combination with the LFU, the minimum inhibitory concentrations (MICs) of gentamicin for P. aeruginosa and E. coli were reduced from 4 to 3 μg/ml and 6 to 3 μg/ml, respectively, and the viability of bacteria decreased by several orders of magnitude. However, ultrasonic treatment enhanced activity of antibiotics was not observed with Gram-positive S. epidermidis and S. aureus. Williams and Pitt [15] also observed the combined effect of gentamicin and LFU against E. coli. The greatest bactericidal effect (approximately 5 log reductions in viable population) was realized with continuous ultrasonic insonation at 70 kHz and 4.5 W/cm2. Zhu et al. [16] confirmed that microbubble-mediated LFU could further enhance the antimicrobial efficacy of gentamicin compared with LFU alone. These might be because the addition of external microbubbles strengthened the cavitation, created more pores, and drove more drugs through bacterial cell membrane (Figure 1). Rapoport et al. [17] applied a spin-labeled gentamicin bioreduction kinetics model to reveal the mechanism of this synergism against Gram-negative P. aeruginosa and E. coli. Hydrophilic gentamicin is assumed to function through porin channels in the outer cell membranes. The results showed the penetration of spin-labeled gentamicin was not affected by continuous insonation with intensity below the cavitation threshold (2.4 W/cm2), implying that the synergistic effect between hydrophilic antibiotics and LFU in killing Gram-negative bacteria did not result from the enhanced antibiotic penetration through bacterial cell walls. They speculated that it might be caused by the effect of ultrasound on interaction of antibiotics with bacterial cells. It has been reported that although P. aeruginosa is resistant to erythromycin (MIC between 350 and 250 μg/ml), combination of erythromycin with continuous LFU at 70 kHz and 2.2 W/cm2 LFU enhanced the bactericidal effect of 125 μg/ml erythromycin against P. aeruginosa [18]. Rapoport et al. [19] found that application of continuous ultrasound to suspended P. aeruginosa cells resulted in increased uptake of hydrophobic antibiotic erythromycin. This effect was different from that on hydrophilic antibiotics because the penetration of lipophilic compounds proceeds through the phospholipid bilayers rather than the porin channels. The data suggested that, in contrast to porin channels, phospholipid bilayers are perturbed by insonation, forming some transient defects responsible for the enhanced penetration of lipid-soluble substances. The effect was transient because the initial membrane permeability was restored after the termination of insonation. Runyan et al. [20] found that the rate of nitrocefin hydrolysis, which reflects the entry rate of antibiotics, in suspension of P. aeruginosa was increased by application of continuous ultrasound in an intensity-dependent manner. Liu et al. [21] evaluated the antibacterial effect of fluoroquinolones (levofloxacin and ciprofloxacin) on E. coli with and without stimulation of continuous ultrasound at 40 kHz and found that addition of LFU enhanced the killing rate of fluoroquinolone to E. coli by 10–30% compared with fluoroquinolone alone. Moreover, they found that O2− and OH produced through combined effect of LFU and fluoroquinolones might be the main reason for the enhanced bactericidal effect. Rediske et al. [22] compared the action of LFU combined with antibiotics on several bacterial species. They found that gentamicin, kanamycin, or streptomycin at MIC level in combination with continuous ultrasound decreased viability of E. aerogenes by 4-, 2-, and 1-log degree than exposure to antibiotic alone for 3 h. The killing rate of gentamicin at the MIC in combination with ultrasound on S. marcescens and S. derby was 2-3 logs greater than that with antibiotic alone.

Although Pitt et al. [14] showed that LFU alone did not enhance gentamicin activity against Gram-positive strains, combination of LFU with other antibiotics showed synergistic bactericidal effect on S. aureus and S. epidermidis (Table 1). Ayan et al. [23] investigated the effects of eight antibiotics, namely, penicillin, oxacillin, erythromycin, teicoplanin, vancomycin, clindamycin, levofloxacin, and ciprofloxacin, in combination with LFU, and found combined treatment of antibiotics with continuous LFU at 1.5 MHz and 30–161 mW/cm2 significantly lowered the number of bacterial colonies compared with that of treatment with antibiotics alone (). Conner-Kerr et al. [24] conducted an in vitro study to determine the effects of continuous LFU delivered at 35 kHz and 2 W/cm2 on bacterial viability, cell wall structure, and colony characteristics, including antibiotic resistance on Methicillin-resistant S. aureus (MRSA). They found that combined treatment of LFU increased the inhibition zone of 1 μg oxacillin on MRSA plates to above 13 mm, the critical value for determining antibiotic resistance, indicating that combined treatment of LFU decreased bacterial resistance to oxacillin. Rediske et al. [22] reported that bactericidal effect of ampicillin in combination with continuous ultrasound at 70 kHz and 3 W/cm2 against S. epidermidis was 1.5 logs greater than that of ampicillin alone.

At present, only in vitro experiments were applied against planktonic bacteria. Using in vitro experiments can easily determine the antibacterial effect and quickly suggest whether the combination of LFU and specific antimicrobial agents has a synergistic antibacterial effect on a certain bacterium. Most of these studies applied continuous ultrasound with frequency ranging from 35 to 70 Hz and intensity lower than 4.7 W/cm2. Only one study applied higher frequency (1.5 MHz) and also showed the synergistic bactericidal effect with antibiotics. Although these results are promising, differences in the critical ultrasound parameters among these studies are evident. Especially for ultrasound time, some studies showed obvious synergism after exposure to LFU within 30 min, while others apply continuous ultrasound for 24 h or even longer.

3. Synergistic Effects of LFU and Antibiotics against Biofilm

Biofilms are microbes attached to surfaces or to each other in aggregates or clumps. Biofilms show extreme tolerance to antimicrobials and host defenses and can withstand 100–1000 times higher antimicrobial concentrations than planktonic counterparts [25]. Therefore, biofilm caused infection has always been a troubling clinical problem.

Reports of synergistic effects of LFU and antibiotics against biofilm were summarized in Table 2. Qian et al. [26] conducted a series of experiments to test the synergism effect of LFU and gentamicin on biofilm of P. aeruginosa. First, they found that continuous LFU at 500 kHz and 10 mW/cm2 enhanced the bactericidal effect of gentamicin against 24 h old biofilm. In addition, confocal scanning laser microscopy (CSLM) showed that LFU at 10 mW/cm2 did not disrupt biofilm. Therefore, they hypothesized that there is minimal concern that ultrasonic treatment of an implant infection would break up and disseminate clusters of biomass to other parts of the body. Then they compared the effect of ultrasound at different frequencies of 70 kHz, 500 kHz, 2.25 MHz, and 10 MHz, respectively, and at power density of 10 mW/cm2. The results indicated lower frequency ultrasound was significantly more effective than higher frequency ultrasound in reducing bacterial viability within the biofilm [27]. In another study they found that continuous waveform ultrasound at frequency of 70 kHz and power density of 10 mW/cm2 was more effective in enhancing antibiotic bactericidal effect than that at intensity of 1 mW/cm2 and pulsed waveform ultrasound with a burst power density appeared to be as effective as continuous ultrasound at the same power density [28]. Based on these studies, Qian et al. [28] conducted a comprehensive analysis about the possible mechanisms in light of the observed influence of various ultrasonic parameters on the enhanced action of gentamicin against biofilms. First they rejected the hypothesis of oscillatory shear inducing antibiotic uptake. Because mathematical analysis of oscillatory shear stress on the cell shows that the magnitude of stress increases with frequency, the bactericidal effect of ultrasound decreases with its frequency. They also ruled out the existence of transient cavitation in the bioacoustic effect. There is no difference between the viability of the control biofilm and the biofilm exposed to ultrasound only. This indicates that the cells are not killed by the free radicals or extreme environment produced by transient cavitation and the observed bioacoustic effect is related to the temporal peak intensity, not the temporal average intensity of ultrasound. If transient cavitation were involved, the bactericidal effect would be a function of temporal average intensity, not peak intensity. Finally, because the dependence upon peak power density suggests that acoustic pressure plays a significant role, they speculated it is possible that stable cavitation and the accompanying microstreaming contribute to the bioacoustic effect.

Some in vitro and in vivo experiments aimed at biofilm of E. coli also showed enhanced efficacy of gentamicin by LFU. An in vitro study found that, after 6 h of combined gentamicin and ultrasound treatment, a single-species E. coli biofilm showed no reproductive ability. The combination of continuous wave ultrasound at 70 kHz with gentamicin significantly reduced bacterial viability compared with antibiotic alone and resulted in about 97% killing within 2 h. When the exposure time was extended to 6 h, the combination of ultrasound and gentamicin completely inhibited the reproductive ability of the biofilm. However, the combination of 500 kHz ultrasound and antibiotic produced only a slight reduction [29]. Rediske et al. [30] developed an in vivo rabbit model with biofilm-infected disks implanted to determine if continuous ultrasound at 28.48 kHz could enhance the effects of gentamicin. They found that treatment alone with ultrasound at 100 mW/cm2 did not affect the viable counts of bacteria, but treatment with antibiotic plus ultrasound reduced the viable counts of bacteria by 2.39 fold () compared with treatment with antibiotic alone. In addition, treatment with ultrasound at 100 mW/cm2 showed no damage to the rabbit skin, but treatment with ultrasound at 300 mW/cm2 did. To minimize the skin damage, they evaluated the pulsed ultrasound at 300 or 600 mW/cm2 in a pulse of 100 cycles with a 1 : 3 or 1 : 6 duty cycle, wherein the temporal average intensity was 100 mW/cm2, and found that ultrasound enhanced the action of gentamicin in killing E. coli but did not damage skin at pulse or continuous intensity of at least 300 mW/cm2 and an average intensity of 100 mW/cm2 [31].

Carmen et al. [32] conducted in vitro and in vivo researches on LFU combined with gentamicin or vancomycin against P. aeruginosa and E. coli biofilm. Their in vitro study using colony biofilms found that ultrasound at 70 kHz and 1.5 W/cm2 can significantly increase gentamicin transport through biofilms and 45 min of insonation can double the amount of gentamicin in E. coli biofilm compared to their noninsonated counterparts. In addition, no detectable gentamicin penetrated P. aeruginosa biofilms without ultrasound. But more than 0.45 mg gentamicin was collected after 45 min of insonation. Their in vivo study on rabbits implanted subcutaneously with infected biofilm disks showed that application of pulsed ultrasound in a 1 : 3 duty cycle at 28.5 kHz and 500 mW/cm2 with 48 h of gentamicin treatment resulted in a significant reduction of  CFU/cm2 in E. coli biofilm. However, 24 or 48 h of ultrasound combined with gentamicin failed to significantly enhance the killing of P. aeruginosa in the biofilm. This difference may be related to the documented difference in outer membrane permeability between P. aeruginosa and E. coli [33]. In another study, they found that S. epidermidis biofilms responded favorably to combinations of ultrasound and vancomycin, because 48 h of ultrasound significantly reduced viable bacteria in the biofilm by 2.08  CFU/cm2 [34].

Seth et al. [35] used a rabbit in vivo wound biofilm model. They topically applied ciprofloxacin on postoperative day 4 to eliminate planktonic P. aeruginosa and an antimicrobial absorbent dressing containing polyhexamethylene biguanide to prevent regrowth of planktonic bacteria and carried out LFU treatment every other day or every day. They found that applications of LFU significantly impacted biofilm-infected wounds, including a decrease in viable bacteria, as well as an overall improvement in wound healing and host inflammatory dynamics. Human β-defensin 3 (HBD-3) is a promising cationic antimicrobial peptide for future bactericidal employment. One study showed that biofilm density, the percentage of live cells, and the viable count of Staphylococcus that recovered from the biofilm on the titanium surface in mice were significantly decreased after combined treatment of HBD-3 with ultrasound. Moreover, ultrasound could enhance HBD-3 activity of inhibiting the biofilm-associated genes expression [36]. Liu et al. [37] found that although application of LFU (40 kHz, 600 mW/cm2, 30 min, duty cycle 1 : 9) alone or in combination with single antibiotic (colistin or vancomycin) failed to significantly reduce bacteria counts in A. baumannii biofilms, application of LFU in combination with both colistin and vancomycin apparently had more effective antibacterial function against biofilm.

Both the in vitro and animal model studies have been applied in the LFU combinations studies against biofilm. In addition to confirming that LFU has a synergistic antimicrobial effect on biofilms, these series studies further clarified three key issues. First, at the same intensity, lower frequency ultrasound is more effective than higher frequency ultrasound in reducing bacterial viability within the biofilm. Secondly, synergistic antimicrobial effect of pulsed-wave ultrasound is related to the temporal peak intensity, not the temporal average intensity of ultrasound. Thirdly, skin damage is related to the average intensity of ultrasound. The higher the average ultrasound intensity, the greater the damage to the skin. These suggest that maximum sterilization and minimized damage to skin can be achieved by adjusting the duty cycle of pulsed LFU. From the in vivo data included in these reviews, although the study design was different, LFU at 20–30 kHz with the intensity range from 200 to 500 mW/cm2 seems to have most successful outcomes in enhancing bactericidal effect against biofilm.

4. Effect of LFU on Antibiotic Release from Implanted Material

The high incidence of device-related biofilm infections has spurred a rapidly growing field of research directed at controlling or eliminating biofilm formation. Various device-related infections have been well documented on vascular catheters as well as prosthetic hips, knees, and other orthopedic implants [38]. In recent years great efforts have been devoted to create biocompatible materials that prevent or minimize biofilm infection by inhibiting the formation and survival of biofilms. One strategy is to incorporate antibiotics into the devices or materials, which targets the site where biofilm formation is likely to occur. LFU plays an important role in facilitating antibiotic release. For example, Norris et al. [39] assessed the efficacy of ultrasonically controlled release of ciprofloxacin from self-assembled coatings on poly(2-hydroxyethyl methacrylate) hydrogels against P. aeruginosa biofilm and showed application of LFU enhanced release of ciprofloxacin, which was retained inside the polymer in the absence of ultrasound. And biofilm accumulation on ciprofloxacin-loaded hydrogels with ultrasound-induced drug delivery was significantly reduced compared to that in the control experiments (Table 3).

The most frequently reported research on LFU promotes the release of antibiotics was about bone cement (Table 3). Hendriks et al. [40] first compared the response of three commercially available bone cements to ultrasound and found a striking increased release of gentamicin upon ultrasound at 46.5 kHz and 167 mW/cm2. They also carried a series experiment to test the effects of LFU on gentamicin-loaded beads or bone cements by measuring gentamicin release from both materials after 18 h of exposure in PBS and found that ultrasound significantly increased gentamicin release from beads, but only marginally from bone cements [41]. Then they investigated the effect of gentamicin released from bone cements treated with LFU on 4 strains derived from patients, including E. coli, S. aureus, coagulase-negative staphylococci, and P. aeruginosa. They found that ultrasound plus gentamicin further reduced bacterial viability of both planktonic and biofilm bacteria and the percentage of reduction was higher for biofilm bacteria than for planktonic bacteria. They speculated that this was probably due to the slow diffusion of the released antibiotic through the biofilm in the suspension, causing a higher local concentration of antibiotic in the biofilm than in suspension [42]. Moreover, LFU in combination with different administration of gentamicin on bone cements was assessed in rabbit model. Compared to the negative controls, ultrasound resulted in more than 50% enhancement in bacterial killing in combination with both systemic gentamicin and gentamicin released from antibiotic-loaded bone cement [43].

Cai et al. [44] investigated the effect of pulsed-wave LFU on the antimicrobial efficacy of vancomycin on acrylic bone cement. After implanting cement and inoculating S. aureus into the bilateral hips of rabbits, ultrasound was applied to animals in the normal ultrasound group at 0–12 h of postoperation and to those in the delayed-ultrasound group at 12–24 h of postoperation. The results showed that the length of time when local drug level exceeded the minimum inhibitory concentration () was significantly prolonged in the delayed-ultrasound group compared with that in the ultrasound untreated or normal ultrasound groups. In addition, bacterial densities in both right hip aspirates and right femoral tissues at 48 h reduced the most in the delayed-ultrasound group. They also revealed that intermittent ultrasonication (a 10 min pause between two 40-min ultrasonic periods) improved vancomycin release from cement in view of prolonged compared with continuous ultrasonication [10]. The mechanisms involved in the ultrasound-enhanced drug release from cement were attributed most to the nonthermal effect of ultrasound, mainly the stable cavitation and the radiation pressure, which generate multidirectional acoustic microstreams. The microstream produced a high shear stress at drug-cement interfaces, allowing detachment of drug grains from the surface. Meanwhile, the microstream pushed solution into acrylic matrix via craters and channels (Figure 2) [10]. They further investigated whether microbubbles-mediated ultrasound could facilitate vancomycin elution from cylindrical specimens and enhance activity of the eluted antibiotic against S. aureus. The in vitro and in vivo results all showed that both elution and activity of vancomycin were significantly higher in vancomycin + microbubbles + ultrasound specimen than in vancomycin or vancomycin + ultrasound specimens [45].

Yan et al. [46] investigated the enhancement of continuous ultrasound on vancomycin release and antimicrobial efficacy of antibiotic on acrylic bone cement. The results showed that ultrasound increased the drug elution by 2.57–27.44% when compared with the controls in vitro. Vancomycin concentrations in the rabbit hip cavity and urinary elimination of vancomycin were both measured after exposure to ultrasound. The results showed that continuous ultrasound increased local by 47.6 mg/mL and urinary elimination of vancomycin by 109.56 mg but failed to prolong the local . Wendling et al. [47] developed a study to determine the effect of different mixing techniques of vancomycin-impregnated polymethylmethacrylate cement with LFU on antibiotic elution. They found that the combination of a delayed mix technique with LFU treatments could significantly increase both short- and long-term antibiotic elution without affecting mechanical strength.

Pulse ultrasound is most commonly applied in these studies. Some studies have evaluated the synergistic antimicrobial effects of LFU using pharmacokinetics/pharmacodynamics and demonstrate the ability of LFU in promoting drug release in bone cement. However, in addition to the frequency, many other factors also affect the release of antibiotics, such as intensity and the treatment duration time of LFU itself, bone cement type, mixing technique, and the beginning ultrasound time after implantation. At the same time, only a few studies examined the effect of ultrasound on the physical properties of the implant. According to the current limited results, it can only be roughly speculated that 20–50 kHz and 100–300 mW/cm2 are relatively effective frequency and intensity range of LFU in promoting antibiotic release from implanted materials. However, more comprehensive and in-depth research is still needed.

5. Clinical Practice of LFU and Antibiotic Combination Therapy

As a therapeutic adjuvant, LFU has been extensively studied in chronic wound healing and offers relatively painless debridement and bacterial biofilm destruction. For example, Breuing et al. [48] explored the effect of LFU on wounds in 17 patients and found that wound was healed in 9 (53%) patients with or without the aid of skin grafts and reduced by at least 50% in size in 6 (35%) and by 20%–30% in 2 patients. In addition, no patients required initiation of antibiotic treatment after starting LFU. Tewarie et al. [49] compared the ultrasonic debridement () with conventional surgical therapy () in removing bacterial biofilms and preservation of vital sternal tissue in 37 consecutive patients. Time to secondary wound closure following eradication was significantly shortened in LFU group. Postoperative antibiotic treatment time and recurrence of sternocutaneous fistula also showed a trend in favor of LFU group. However, only few clinical reports exist on the combined application of LFU and antibiotics. Only Komrakov and Antipov [50] reported that combined use of LFU and gentamycin solution for treatment of wounds in 17 patients reduced the critical level of bacterial wound colonization. They found that this combination could decrease the incidence of purulent-septic complications from 35.7 to 5.9%. There was no wound suppuration in 14 patients after the operations for late reocclusion performed in the presence of cicatrices of the tissues.

6. Conclusions

Based on the available in vitro and in vivo data, it can be concluded that LFU can assist the antibiotic action on both planktonic and biofilm bacteria. For antibiotic imbedded implants, LFU can promote the release of antibiotics to achieve the optimal efficacy. However, there is still a long way to go before clinical application of combination therapy of LFU with antibiotics. First of all, the current studies involved a narrow range of susceptible pathogens. There are very few studies on the most threatening MDR bacteria. Secondly, frequency, intensity, and pulse cycle varied a lot at present. The promising frequency and intensity from in vitro studies are likely to cause local damage in in vivo studies [30, 31]. Therefore, LFU parameters appropriate for clinical application need to be further explored. Thirdly, one study indicated that LFU treatment reduced the interface shear strength and initial stability of vancomycin-loaded acrylic bone cement-stem [51]. So the impact of LFU on the physical properties of the implant materials requires a comprehensive examination. At last, because bacteria will partially be removed from the biofilm surface when LFU is applied [52], whether it will bring the risk of spreading the pathogens and forming systemic bloodstream infection also requires more careful evaluation.

Disclosure

The authors alone are responsible for the content and writing of the paper. The funders had no role in study design, data collection and analysis, decision to publish, and manuscript preparation.

Conflicts of Interest

The authors report no conflicts of interest.

Authors’ Contributions

Yun Cai and Jin Wang contributed equally to this review.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (no. 81573472) and Clinical Research Support Funding of PLA General Hospital (no. 2015 FC-TSYS-1042).